NeoGenomics (NEO) Reports In-Line Q1 EPS, Guides FY Revenue Below Estimates, FY EPS In-Line
NeoGenomics (NASDAQ: NEO) reported Q1 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $61.7 million versus the consensus estimate of $61.35 million.
GUIDANCE:
NeoGenomics sees FY2017 EPS of $0.17-$0.21, versus the consensus of $0.19. NeoGenomics sees FY2017 revenue of $255-265 million, versus the consensus of $264.6 million.
For earnings history and earnings-related data on NeoGenomics (NEO) click here.